Physician profile
Jimmy R Mascaro
NPI 1104998251
$360,783.62
in general payments reported to CMS, 2019-2025
16 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $41K · 2021: $55K · 2022: $50K · 2023: $45K · 2024: $37K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $155K · Travel and Lodging: $23K · Food and Beverage: $7,658 · Consulting Fee: $1,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $154,935.00 |
| Travel and Lodging | $22,953.19 |
| Food and Beverage | $7,657.55 |
| Consulting Fee | $1,840.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185,362.89 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $103,530.39 | 2021-2025 | Fanapt |
| Allergan, INC. | $67,579.50 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,840.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $1,455.93 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Lundbeck LLC | $465.70 | 2019-2025 | Abilify Maintena, Rexulti |
| Alkermes, INC. | $161.75 | 2019-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.71 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $71.70 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $70.62 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $58.28 | 2020-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $31.19 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.02 | 2022-2023 | Trintellix |
| Corium, LLC | $20.32 | 2022 | |
| Axsome Therapeutics, INC. | $17.64 | 2025 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Mascaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.